# PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

> **NCT06683612** · PHASE1 · COMPLETED · sponsor: **Contineum Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)
- Idiopathic Pulmonary Fibrosis
- Multiple Sclerosis
- Multiple Sclerosis, MS
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Progressive
- Multiple Sclerosis, Secondary Progressive
- Healthy
- Healthy Volunteers

## Interventions

- **DRUG:** PIPE-791

## Key facts

- **NCT ID:** NCT06683612
- **Lead sponsor:** Contineum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-09
- **Primary completion:** 2025-06-04
- **Final completion:** 2025-06-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683612, "PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06683612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*